Versantis raises funds to advance liver disease drugs
Swiss biotech firm Versantis has completed a series B funding round to support the clinical...
Read More...
Focus:
Switzerland
-
![]()
Marry Jane
Marry Jane (MJ) creates lifestyle products, cosmetics and tobacco substitutes with high-cannabidiol (CBD) / low-tetrahydrocannabinol...
Read More...
-
![Gavi Vaccine Alliance seeks $7. 4bn to immunise 300 million people]()
Gavi Vaccine Alliance seeks $7. 4bn to immunise 300 million people
Gavi, the Vaccine Alliance has initiated a $7.4bn fundraising drive to support the immunisation of...
Read More...
-
![]()
EC approves Roche’s Tecentriq combination to treat breast cancer
Roche has gained approval from the European Commission (EC) for Tecentriq (atezolizumab) with chemotherapy (Abraxane)...
Read More...
-
![Vaxxilon receives grant to develop new prophylactic vaccine]()
Vaxxilon receives grant to develop new prophylactic vaccine
Switzerland-based synthetic vaccines firm Vaxxilon has received a funding grant from CARB-X to support the...
Read More...
-
Sonnet BioTherapeutics agrees to buy Relief Therapeutics
Biotechnology company Sonnet BioTherapeutics has agreed to acquire all outstanding shares of Relief Therapeutics under...
Read More...
-
![Santhera licences Leber’s hereditary optic neuropathy drug Raxone to Chiesi]()
Santhera licenses Leber’s hereditary optic neuropathy drug to Chiesi
Santhera Pharmaceuticals has licensed a drug called Raxone, indicated for the treatment of Leber’s hereditary...
Read More...
-
![manufacture of chemical APIs]()
Switzerland joins major players as home to high containment API manufacturing facilities
The handling of drug substances classed as highly potent or cytotoxic is increasingly commonplace for...
Read More...
-
![Gilead licences three antiviral programmes from Novartis]()
Gilead gets licences to three antiviral programmes from Novartis
Gilead Sciences has secured an antiviral deal with Novartis to gain exclusive global rights to...
Read More...
-
![Boehringer acquires AMAL Therapeutics for $366m]()
Boehringer acquires AMAL Therapeutics for $366m
Boehringer Ingelheim has expanded its cancer immunology portfolio with the acquisition of Swiss biotechnology firm...
Read More...
Close
Close
Close
Go Top
